NVS32b1

NVS32b1 is an **afucosylated monoclonal antibody** that targets CD32b (FcγRIIb), the sole inhibitory Fcγ receptor expressed on B and plasma cells, including their malignant counterparts. Its CDR region binds the CD32b Fc-binding domain with high specificity and affinity, while its afucosylated Fc region enhances activation of FcγRIIIa on immune effector cells. NVS32b1 mediates killing of CD32b+ malignant and healthy B cells via antibody-dependent cellular cytotoxicity, phagocytosis, and complement-dependent cytotoxicity. It also blocks the CD32b Fc-binding domain, minimizing resistance to therapeutic antibodies such as rituximab, obinutuzumab, and daratumumab. The agent demonstrates antitumor and immunomodulatory activity, including recruitment of macrophages and enhancement of dendritic cell maturation. Developed primarily for treatment of CD32b+ B-cell and plasma cell malignancies, especially multiple myeloma, its highest development phase is preclinical[1][3][5].

Brand names

NVS32b1NVS-32b1NVS 32b1

Other names

NVS-32b1NVS32b1NVS 32b1NVS-32b2NVS32b2NVS 32b2